[
  {
    "ts": "2025-12-19T14:51:37+00:00",
    "headline": "I’ll Play, Says Jim Cramer About Bristol-Myers (BMY)",
    "summary": "We recently published 12 Stocks on Jim Cramer’s Radar. Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks aon Jim Cramer’s radar. Bristol-Myers Squibb Company (NYSE:BMY) is one of the largest pharmaceutical companies in the world. The firm has seen some attention from analysts in December. For instance, Jefferies reiterated a Buy rating and a $68 […]",
    "url": "https://finance.yahoo.com/news/ll-play-says-jim-cramer-145137156.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "88cb8784-89b6-3eaa-9dab-dbb33037452d",
      "content": {
        "id": "88cb8784-89b6-3eaa-9dab-dbb33037452d",
        "contentType": "STORY",
        "title": "I’ll Play, Says Jim Cramer About Bristol-Myers (BMY)",
        "description": "",
        "summary": "We recently published 12 Stocks on Jim Cramer’s Radar. Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks aon Jim Cramer’s radar. Bristol-Myers Squibb Company (NYSE:BMY) is one of the largest pharmaceutical companies in the world. The firm has seen some attention from analysts in December. For instance, Jefferies reiterated a Buy rating and a $68 […]",
        "pubDate": "2025-12-19T14:51:37Z",
        "displayTime": "2025-12-19T14:51:37Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/67016191d6d2df48fd6f8c9ec632b347",
          "originalWidth": 1920,
          "originalHeight": 1186,
          "caption": "I'll Play, Says Jim Cramer About Bristol-Myers (BMY)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vJ7lKbloSPByVfgD_gqgZg--~B/aD0xMTg2O3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/67016191d6d2df48fd6f8c9ec632b347.cf.webp",
              "width": 1920,
              "height": 1186,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/szs6fG45A8w_rlV8N_NBzA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/67016191d6d2df48fd6f8c9ec632b347.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ll-play-says-jim-cramer-145137156.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ll-play-says-jim-cramer-145137156.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T13:02:12+00:00",
    "headline": "Why Cytokinetics CEO Is Optimistic As FDA Deadline On Aficamten Looms",
    "summary": "Cytokinetics is on the cusp of its first FDA approval, analysts say, leading up to the agency's decision date for the drug called aficamten.",
    "url": "https://www.investors.com/news/technology/cytokinetics-ceo-robert-blum-fda-decision-aficamten-ohcm/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "8d5f8911-c1c1-3569-b3ab-1cdcf9af25af",
      "content": {
        "id": "8d5f8911-c1c1-3569-b3ab-1cdcf9af25af",
        "contentType": "STORY",
        "title": "Why Cytokinetics CEO Is Optimistic As FDA Deadline On Aficamten Looms",
        "description": "",
        "summary": "Cytokinetics is on the cusp of its first FDA approval, analysts say, leading up to the agency's decision date for the drug called aficamten.",
        "pubDate": "2025-12-19T13:02:12Z",
        "displayTime": "2025-12-19T13:02:12Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/8d5f8911-c1c1-3569-b3ab-1cdcf9af25af/why-cytokinetics-ceo-is.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/a49294d1547dac5f94f8ff5ce500b4a7",
          "originalWidth": 1000,
          "originalHeight": 511,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fxptB0Mc.7PjpZxZUhrHhg--~B/aD01MTE7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/a49294d1547dac5f94f8ff5ce500b4a7.cf.webp",
              "width": 1000,
              "height": 511,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cE7IU62RGFIGAiy9bTHdmw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/a49294d1547dac5f94f8ff5ce500b4a7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/cytokinetics-ceo-robert-blum-fda-decision-aficamten-ohcm/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CYTK"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T09:01:00+00:00",
    "headline": "Global Pulmonary Embolism Market Set for Growth with Increasing DVT and PE Cases",
    "summary": "The global pulmonary embolism market is poised for growth from 2025 to 2035, fueled by rising cases of deep vein thrombosis (DVT) and pulmonary embolism (PE) due to escalating obesity rates and sedentary lifestyles. Key drivers include improved diagnostics, Direct Oral Anticoagulants (DOACs), and heightened awareness. Despite the growth, high treatment costs and complications, such as bleeding risks, pose significant challenges, especially in lower-income regions. Top market players include Sano",
    "url": "https://finance.yahoo.com/news/global-pulmonary-embolism-market-set-090100815.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "01b9f7ad-7529-3a07-953c-137147ab6314",
      "content": {
        "id": "01b9f7ad-7529-3a07-953c-137147ab6314",
        "contentType": "STORY",
        "title": "Global Pulmonary Embolism Market Set for Growth with Increasing DVT and PE Cases",
        "description": "",
        "summary": "The global pulmonary embolism market is poised for growth from 2025 to 2035, fueled by rising cases of deep vein thrombosis (DVT) and pulmonary embolism (PE) due to escalating obesity rates and sedentary lifestyles. Key drivers include improved diagnostics, Direct Oral Anticoagulants (DOACs), and heightened awareness. Despite the growth, high treatment costs and complications, such as bleeding risks, pose significant challenges, especially in lower-income regions. Top market players include Sano",
        "pubDate": "2025-12-19T09:01:00Z",
        "displayTime": "2025-12-19T09:01:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/global-pulmonary-embolism-market-set-090100815.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/global-pulmonary-embolism-market-set-090100815.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SNY"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T14:40:03+00:00",
    "headline": "Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term",
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "url": "https://finance.yahoo.com/news/why-bristol-myers-squibb-bmy-144003728.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "68ab6bfc-4f39-32c9-bf38-79e454dfe591",
      "content": {
        "id": "68ab6bfc-4f39-32c9-bf38-79e454dfe591",
        "contentType": "STORY",
        "title": "Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term",
        "description": "",
        "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
        "pubDate": "2025-12-19T14:40:03Z",
        "displayTime": "2025-12-19T14:40:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/71afbbc0512eb3c471136d93f39079c9",
          "originalWidth": 900,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Ucluz4bedY7Dxd_XS4xCHQ--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/71afbbc0512eb3c471136d93f39079c9.cf.webp",
              "width": 900,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Asv6z7WU__xaJFJkAJhxZQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/71afbbc0512eb3c471136d93f39079c9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-bristol-myers-squibb-bmy-144003728.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-bristol-myers-squibb-bmy-144003728.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T19:44:47+00:00",
    "headline": "Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump",
    "summary": "Dow Jones stock Merck struck a Most Favored Nation agreement with the Trump administration on Friday, joining other pharma bellwethers.",
    "url": "https://www.investors.com/news/technology/merck-most-favored-nation-drug-pricing-deal/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "2cb395b6-a638-3e88-a9aa-fb560f3deaa3",
      "content": {
        "id": "2cb395b6-a638-3e88-a9aa-fb560f3deaa3",
        "contentType": "STORY",
        "title": "Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump",
        "description": "",
        "summary": "Dow Jones stock Merck struck a Most Favored Nation agreement with the Trump administration on Friday, joining other pharma bellwethers.",
        "pubDate": "2025-12-19T19:44:47Z",
        "displayTime": "2025-12-19T19:44:47Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/2cb395b6-a638-3e88-a9aa-fb560f3deaa3/dow-jones-merck-other.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/3a897c85d50513809da70438e2285a69",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J52TnzuAhPRkxQcQYwjwUg--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/3a897c85d50513809da70438e2285a69.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Jcx0qKVoS.mXc1N2ud7p5Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/3a897c85d50513809da70438e2285a69.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/merck-most-favored-nation-drug-pricing-deal/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "SNY"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T16:48:33+00:00",
    "headline": "Top Midday Stories: Oracle, Others Form JV to Oversee TikTok in US; More Drugmakers to Announce US Drug Price Deals",
    "summary": "All three major US stock indexes were up in late-morning trading Friday, as the artificial-intellige",
    "url": "https://finance.yahoo.com/news/top-midday-stories-oracle-others-164833427.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "1761f90c-fb96-3c96-96e0-69080592861e",
      "content": {
        "id": "1761f90c-fb96-3c96-96e0-69080592861e",
        "contentType": "STORY",
        "title": "Top Midday Stories: Oracle, Others Form JV to Oversee TikTok in US; More Drugmakers to Announce US Drug Price Deals",
        "description": "",
        "summary": "All three major US stock indexes were up in late-morning trading Friday, as the artificial-intellige",
        "pubDate": "2025-12-19T16:48:33Z",
        "displayTime": "2025-12-19T16:48:33Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/top-midday-stories-oracle-others-164833427.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/top-midday-stories-oracle-others-164833427.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ORCL"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "FOLD"
            },
            {
              "symbol": "BMRN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T16:42:00+00:00",
    "headline": "White House Will Announce Pricing Deals With More Drugmakers Friday",
    "summary": "The Trump administration has talked tough about cutting drug prices, but the impacts of the deals with drug companies announced thus far have been limited.",
    "url": "https://www.barrons.com/articles/trump-drug-prices-pharmaceutical-9a04e4f5?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "af431dd1-182d-36f0-bd26-58acf64a3210",
      "content": {
        "id": "af431dd1-182d-36f0-bd26-58acf64a3210",
        "contentType": "STORY",
        "title": "White House Will Announce Pricing Deals With More Drugmakers Friday",
        "description": "",
        "summary": "The Trump administration has talked tough about cutting drug prices, but the impacts of the deals with drug companies announced thus far have been limited.",
        "pubDate": "2025-12-19T16:42:00Z",
        "displayTime": "2025-12-19T16:42:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/af431dd1-182d-36f0-bd26-58acf64a3210/white-house-will-announce.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/b84973a4d2302435aaade39667770556",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0M1QXHPJoerma0suNcmL3w--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/b84973a4d2302435aaade39667770556.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/S12Xvmf6XJVD1f.9zynb9A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/b84973a4d2302435aaade39667770556.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/trump-drug-prices-pharmaceutical-9a04e4f5?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T15:50:00+00:00",
    "headline": "No, Elon Musk Did Not Buy This Penthouse. It’s Up for Sale.",
    "summary": "The estate of late beauty mogul Sydell Miller’s is now listing the roughly 20,000-square-foot unit for $78.9 million, ending rumors the tech billionaire bought it late last year.",
    "url": "https://www.wsj.com/real-estate/luxury-homes/sydell-miller-west-palm-beach-penthouse-5c0ebda8?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "7cbaeef0-8a89-3c41-ba55-5248ba6dc020",
      "content": {
        "id": "7cbaeef0-8a89-3c41-ba55-5248ba6dc020",
        "contentType": "STORY",
        "title": "No, Elon Musk Did Not Buy This Penthouse. It’s Up for Sale.",
        "description": "",
        "summary": "The estate of late beauty mogul Sydell Miller’s is now listing the roughly 20,000-square-foot unit for $78.9 million, ending rumors the tech billionaire bought it late last year.",
        "pubDate": "2025-12-19T15:50:00Z",
        "displayTime": "2025-12-19T15:50:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/7cbaeef0-8a89-3c41-ba55-5248ba6dc020/no-elon-musk-did-not-buy.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/d8a6b0b14d951326eca73267f20878da",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QL5iT8gtUOhlsjhlirl7gg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/d8a6b0b14d951326eca73267f20878da.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WNZwURu45JGqHwhb16oXEg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/d8a6b0b14d951326eca73267f20878da.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/real-estate/luxury-homes/sydell-miller-west-palm-beach-penthouse-5c0ebda8?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T15:32:00+00:00",
    "headline": "Can Merck Successfully Steer Through the Upcoming Headwinds?",
    "summary": "MRK faces looming Keytruda LOE, falling Gardasil sales and pricing pressure, but new products, pipeline and planned cost savings aim to offset the headwinds.",
    "url": "https://finance.yahoo.com/news/merck-successfully-steer-upcoming-headwinds-153200933.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "6b05d209-9756-31cc-b401-e6f59b677ca5",
      "content": {
        "id": "6b05d209-9756-31cc-b401-e6f59b677ca5",
        "contentType": "STORY",
        "title": "Can Merck Successfully Steer Through the Upcoming Headwinds?",
        "description": "",
        "summary": "MRK faces looming Keytruda LOE, falling Gardasil sales and pricing pressure, but new products, pipeline and planned cost savings aim to offset the headwinds.",
        "pubDate": "2025-12-19T15:32:00Z",
        "displayTime": "2025-12-19T15:32:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/1b28b8f55ab25205feceb1a2771a2b3a",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RRg0vYpNavphT7S8O9jT7w--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1b28b8f55ab25205feceb1a2771a2b3a.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hIkvgr9e5vaptAEV_vkcVg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1b28b8f55ab25205feceb1a2771a2b3a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-successfully-steer-upcoming-headwinds-153200933.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-successfully-steer-upcoming-headwinds-153200933.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "RHHBY"
            },
            {
              "symbol": "RHHVF"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]